Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 127 for:    exosomes

Dendritic Cells-Derived Exosomes in Human Sepsis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02957279
Recruitment Status : Unknown
Verified November 2016 by Jianan Ren, Jinling Hospital, China.
Recruitment status was:  Recruiting
First Posted : November 7, 2016
Last Update Posted : November 7, 2016
Sponsor:
Information provided by (Responsible Party):
Jianan Ren, Jinling Hospital, China

Brief Summary:
The amount of peripheral blood exosomes has been confirmed to change in the endotoxin-induced infection. The primary objectives of this study are to compare the changes of peripheral blood dendritic cell-derived exosomes in the patients with sepsis and the healthy controls.

Condition or disease Intervention/treatment
Sepsis Drug: Antibiotics

Detailed Description:
This is a prospective, single-centered, clinical cohort study.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Cohort Study to Investigate the Impacts of Peripheral Blood Dendritic Cells-Derived Exosomes at Early Phase on the Prognosis in Human Sepsis
Study Start Date : November 2016
Estimated Primary Completion Date : September 2017
Estimated Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Group/Cohort Intervention/treatment
Sepsis group
The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).
Drug: Antibiotics
In the sepsis group, antibiotics were used when needed.

Healthy control group
Healthy volunteers.



Primary Outcome Measures :
  1. Amount of dendritic cell-derived exosomes [ Time Frame: The first 4 hour after admission ]

Secondary Outcome Measures :
  1. Compositions of microRNA in the dendritic cell-derived exosomes [ Time Frame: The first 4 hour after admission ]

Biospecimen Retention:   Samples With DNA
peripheral venous blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients were admitted to Jinling Hospital from November, 2016.
Criteria

Inclusion Criteria:

  • Patients were selected with the diagnostic standard "Sepsis 3.0".
  • Healthy volunteers do not have serious illness.

Exclusion Criteria:

  • Patients or volunteers do not agree to provide written informed consent and / or can not be legally authorized to provide informed consent.
  • Patients give up treatments.
  • Patients or volunteers withdrew from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02957279


Contacts
Layout table for location contacts
Contact: Jianan Ren, MD 862580860108 jiananr@gmail.com
Contact: Yuan Li, MD 8615751866716 liyuan9006@gmail.com

Locations
Layout table for location information
China, Jiangsu
Jinling Hospital, Medical School of Nanjing University Recruiting
Nanjing, Jiangsu, China, 210002
Contact: Jianan Ren, MD    862580860108    jiananr@gmail.com   
Contact: Yuan Li, MD    8615751866716    liyuan9006@gmail.com   
Sponsors and Collaborators
Jinling Hospital, China
Investigators
Layout table for investigator information
Principal Investigator: Jianan Ren, MD Jinling Hospital, Medical School of Nanjing University

Layout table for additonal information
Responsible Party: Jianan Ren, President of department of surgery, Jinling Hospital, Jinling Hospital, China
ClinicalTrials.gov Identifier: NCT02957279     History of Changes
Other Study ID Numbers: 20161103
First Posted: November 7, 2016    Key Record Dates
Last Update Posted: November 7, 2016
Last Verified: November 2016
Keywords provided by Jianan Ren, Jinling Hospital, China:
sepsis
exosomes
dendritic cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Sepsis
Toxemia
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents